All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Biogen Seeks FDA Approval for a Higher Dosing Regimen of Spinraza for Spinal Muscular Atrophy
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken 14 days apart can deliver significant clinical benefits in patients with spinal muscular atrophy.
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular Development Unit at Biogen.
FDA and EMA Accepts Applications for New Nusinersen Regimen
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
Biogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of its blockbuster spinal muscular atrophy (SMA) drug Spinraza. This new proposed dosing regimen simplifies administration by offering two initial 50 mg doses spaced 14 days apart,
Ionis stock rises on FDA, EMA nod for SMA drug dose increase
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a higher dose regimen of its spinal muscular atrophy (SMA) drug,
GlobalData on MSN
3d
Biogen’s higher dose Spinraza under review by US and EU regulators
Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.
IFLScience on MSN
3d
New Breast Cancer Drug Kills Mouse Tumors In Single Dose
More testing is needed, but if the same results are seen in humans, it could transform treatment of the disease.
News Medical
2d
Low-dose initiation of buprenorphine for people using fentanyl fails to deliver expected results
During the COVID-19 pandemic, when fentanyl overdoses surged, doctors were desperate to find ways of helping their patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Los Angeles wildfire updates
Colombia tariffs paused
Graham on Jan. 6 pardons
DOJ drops case
Sentenced to 17+ years
IA immigration law blocked
Chiefs beat Bills
US lifts bomb restrictions
Shifts view on COVID origins
38 hurt on United flight
Win sixth ice dance title
Confirmed to lead Pentagon
Wins US figure skating title
Proposed ban withdrawn
Smuggling deaths guilty plea
Israel, Lebanon extend truce
PETA activists arrested
Hack impacted 190M
ISR to get 2K-pound bombs
‘Walk It Out’ rapper dies
Indicted for insurrection
NK tested cruise missiles?
Escaped monkeys captured
Recalls over 80,000 SUVs
Nets retire No. 15 jersey
Eagles defeat Commanders
Wins first Grand Slam title
153 war detainees freed
Assault trial begins
Feedback